Moderna, Inc. $MRNA Position Lifted by NFSG Corp

Posted by George Bondi on Oct 16th, 2026

NFSG Corp boosted its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 2,581.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,362 shares of the company’s stock after acquiring an additional 5,162 shares during the quarter. NFSG Corp’s holdings in Moderna were worth $1,033,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. BlackRock Inc. acquired a new position in shares of Moderna during the 2nd quarter worth $2,142,877,000. Theleme Partners LLP acquired a new stake in shares of Moderna in the second quarter valued at about $564,272,000. Merck & Co. Inc. acquired a new stake in shares of Moderna in the second quarter valued at about $161,642,545. Bamco Inc. NY acquired a new stake in shares of Moderna in the second quarter valued at about $139,317,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Moderna in the second quarter valued at about $119,168,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Mock sold 34,836 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the sale, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. This trade represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 118,882 shares of company stock worth $16,862,280. 10.80% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of research analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a report on Friday, August 21st. Citigroup cut shares of Moderna from a “neutral” rating to a “sell” rating and increased their target price for the company from $60.00 to $80.00 in a report on Wednesday, September 30th. Barclays lifted their price target on shares of Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a research report on Monday, August 24th. William Blair started coverage on shares of Moderna in a research report on Friday, August 28th. They set an “outperform” rating for the company. Finally, Bank of America boosted their price target on Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Seven analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $101.45.

Get Our Latest Stock Analysis on MRNA

Key Moderna News

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Investor enthusiasm is building ahead of data from Moderna and Merck’s personalized melanoma vaccine program. The companies’ mRNA cancer-vaccine partnership is the primary catalyst behind the recent surge, with investors hoping clinical results could validate a major new growth market. Moderna outweighs bearish views ahead of cancer vaccine data
Positive Sentiment: Merck’s chief executive said the companies expect manufacturing of their cancer vaccine to become faster over time. He described the production process as complex but increasingly well controlled, addressing an important potential commercialization concern. Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
Positive Sentiment: Goldman Sachs raised its Moderna price target to $137 from $120 while retaining a Neutral rating. Although the target remains well below the current trading level, the increase reflects improved expectations ahead of the melanoma data. MRNA Stock Hits Fresh 52-Week Highs As Goldman Raises Target Ahead Of Melanoma Data
Positive Sentiment: Money has rotated into healthcare and away from crowded technology trades, providing an additional momentum tailwind for Moderna and other biotechnology stocks. Moderna Rallies as Money Rotates Into Healthcare
Neutral Sentiment: Moderna’s flu-vaccine opportunity remains prospective; coverage on where consumers can obtain an mRNA flu shot highlights that such products are not yet broadly available, limiting any immediate revenue impact. Where Can I Get an mRNA Flu Shot?
Negative Sentiment: Analysts and commentators warn that the stock’s dramatic year-to-date rebound has outpaced fundamentals. Moderna remains unprofitable, generates negative free cash flow, and is highly dependent on successful pipeline execution. Q3 results on November 6 and Analyst Day on November 12 could produce substantial volatility. Moderna Valuation Is Uncertain
Negative Sentiment: Goldman’s $137 target implies roughly 42% downside from the quoted share price, underscoring the risk that expectations for cancer-vaccine data may already be heavily reflected in Moderna’s valuation. Moderna Stock Is Soaring on Cancer Vaccine Buzz

Moderna Stock Performance

Shares of MRNA stock opened at $236.50 on Friday. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $242.29. The business has a fifty day simple moving average of $153.48 and a 200-day simple moving average of $89.98. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29.

Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The business had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. During the same quarter in the previous year, the company posted ($2.13) EPS. The business’s revenue was up 2.1% on a year-over-year basis. On average, analysts predict that Moderna, Inc. will post -6.11 earnings per share for the current year.

Moderna Profile

(Free Report)

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.